CD28 Market will Reach US$ 2.9 Billion by 2034, Expanding at an 8.02% CAGR

The CD28 Market is expanding as research and therapeutic development increasingly focus on T-cell activation, immune regulation, and targeted immunotherapies. The market is projected to expand from US$ 1.45 billion in 2025 to US$ 2.9 billion by 2034, registering a CAGR of 8.02% during 2026–2034. CD28 is a key costimulatory receptor expressed on T cells and plays an important role in regulating immune responses. Its significance in immunology research, cancer therapeutics, autoimmune disease research, and cell-based therapies is creating opportunities for pharmaceutical, biotechnology, and research-tool companies.

What is driving the market?

The growing focus on T-cell biology and development of immunotherapies is a major factor driving the CD28 market. CD28-mediated costimulation is important for effective T-cell activation and proliferation, making the pathway relevant to research into immune-mediated diseases and cancer. Increasing investment in immuno-oncology and next-generation cellular therapies is encouraging researchers to investigate mechanisms that regulate T-cell responses.

Get a Sample PDF- https://www.theinsightpartners.com/sample/TIPRE00021838

The expansion of cell and gene therapy research is another important market driver. Scientists are studying T-cell activation and costimulatory signaling to improve the performance of engineered immune cells. CD28 signaling has particular relevance in the development and optimization of chimeric antigen receptor T-cell and other adoptive cell therapies.

Growing demand for research reagents, antibodies, proteins, assay systems, and other CD28-related laboratory products is also supporting market development. Pharmaceutical and biotechnology companies, academic institutions, and research laboratories use these tools to investigate immune signaling, therapeutic targets, and disease mechanisms.

Which region leads?

North America represents a significant market for CD28-related research and therapeutic development, supported by a strong biotechnology ecosystem and substantial investment in immunology research. The US has numerous pharmaceutical companies, biotechnology firms, academic research centers, and clinical-development organizations working on immunotherapies and advanced cell-based treatments.

Europe also maintains an important position due to established biomedical research infrastructure and continued development of innovative immunotherapy approaches. Meanwhile, Asia Pacific is creating new opportunities as pharmaceutical and biotechnology capabilities expand across China, Japan, South Korea, India, and other markets. Increasing research investments, growing clinical-development activity, and expanding laboratory infrastructure are contributing to regional demand for immunology research products.

Which segment leads?

Research applications represent a key area within the CD28 market, particularly for immunology and T-cell signaling studies. CD28-related antibodies, proteins, assays, and other research tools are used to investigate costimulatory pathways, immune-cell activation, and interactions between immune cells.

Therapeutic research is another important application area. The CD28 pathway is being investigated in connection with cancer immunotherapy, autoimmune disorders, and cellular therapies. Researchers are examining how modulation of CD28 signaling can influence immune responses and potentially improve therapeutic outcomes.

The growing sophistication of immune profiling and cell-based research is also increasing demand for high-quality and highly specific research reagents. Advances in flow cytometry, single-cell analysis, molecular biology, and cellular assays are enabling more detailed investigation of CD28 expression and signaling mechanisms.

Which companies are prominent?

Key companies analyzed in the CD28 Market include:

Atox Bio Ltd.
Bristol-Myers Squibb Company
Five Prime Therapeutics, Inc.
Johnson & Johnson
TheraMAB LLC
Boster Biological Technology
Aviva Systems Biology Corporation
Biobyt Ltd.
GeneTex, Inc.
ProteoGenix SAS

Competition within the market involves therapeutic development, research reagents, antibody technologies, assay platforms, and related immunology products. Companies are focusing on expanding their research portfolios and developing tools that support the characterization of immune pathways. Pharmaceutical and biotechnology organizations are also investing in novel immunotherapeutic approaches involving T-cell activation and costimulatory mechanisms.

What is changing in 2026?

In 2026, the CD28 market is increasingly influenced by advances in cellular immunotherapy, immune profiling, and precision research. Researchers are placing greater emphasis on understanding how costimulatory pathways affect immune-cell behavior and how these pathways can be manipulated for therapeutic applications.

The continued development of engineered T-cell therapies is increasing interest in costimulatory domains and signaling mechanisms. Researchers are evaluating how different signaling configurations can affect T-cell activation, persistence, and functionality. This is encouraging demand for sophisticated experimental models and molecular research tools.

Single-cell technologies and multiparameter immune profiling are also improving the ability to study CD28 expression and signaling at greater resolution. These approaches can help researchers characterize differences among immune-cell populations and investigate how signaling pathways change in disease and treatment settings.

At the same time, increasing attention to targeted immunomodulation is broadening research into how immune responses can be selectively enhanced or suppressed. This trend is creating opportunities for CD28-focused research across oncology, autoimmune disease, and other immunological fields.

Get Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00021838

What are the major investment opportunities?

Investment opportunities are emerging across immunotherapy research, CD28-targeted technologies, advanced research reagents, and cell-based therapeutic development. Companies developing highly specific antibodies, assay platforms, recombinant proteins, and other research tools can address the growing requirements of pharmaceutical, biotechnology, and academic laboratories.

Cell therapy represents another important opportunity. As researchers continue to optimize engineered immune-cell therapies, understanding the role of costimulatory signaling remains important for developing effective therapeutic platforms. Investments in technologies that enable detailed characterization of T-cell activity can therefore support broader immunotherapy development.

The expansion of biotechnology research infrastructure in emerging markets also provides commercial opportunities for suppliers of CD28-related research products. Partnerships with pharmaceutical companies, biotechnology firms, and academic institutions can help accelerate product adoption and expand research applications.

Through 2034, continued advances in immunology, cellular therapy, immune profiling, and targeted therapeutic development are expected to support demand for CD28-related products and technologies.

Related Reports @

Immunotherapy Drugs Market Share, Demand & Growth by 2034

Cancer Immunotherapy Market Growth, Analysis, and Forecast by 2031

About Us –

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Also Available in : Korean German Japanese French Chinese Italian Spanish